1. Home
  2. RLMD

RLMD

Relmada Therapeutics Inc.

Logo Relmada Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 11:53am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Founded: 2004 Country:
United States
United States
Employees: N/A City: CORAL GABLES
Market Cap: 140.3M IPO Year: N/A
Target Price: $26.00 AVG Volume (30 days): 214.2K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.28 EPS Growth: N/A
52 Week Low/High: $2.36 - $7.22 Next Earning Date: 05-09-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: